David Hudesman
Overview
Explore the profile of David Hudesman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cross R, Sauk J, Zhuo J, Harrison R, Kerti S, Emeanuru K, et al.
Gastro Hep Adv
. 2024 Aug;
1(6):927-935.
PMID: 39131245
Background And Aims: This study aimed to evaluate associations between disease severity, patient-reported outcomes (PROs), and work productivity in patients with inflammatory bowel disease (IBD [Crohn's disease (CD) and ulcerative...
2.
Jang K, Hudesman D, Jones D, Loke P, Axelrad J, Cadwell K
Gastroenterology
. 2024 Aug;
167(7):1453-1456.e5.
PMID: 39094749
No abstract available.
3.
Holmer A, Hudesman D
Curr Gastroenterol Rep
. 2024 Jul;
26(10):263-272.
PMID: 38970743
No abstract available.
4.
Janak J, Loughlin A, Moore P, Lemay C, Mease P, Lebwohl M, et al.
Dig Dis Sci
. 2024 May;
69(8):2784-2795.
PMID: 38811505
Background: Comparisons among autoimmune diseases enable understanding of the burden and factors associated with work productivity loss and impairment. Aims: The objective was to compare work productivity and activity and...
5.
Sands B, DHaens G, Panaccione R, Regueiro M, Ghosh S, Hudesman D, et al.
Clin Gastroenterol Hepatol
. 2024 May;
22(10):2084-2095.e4.
PMID: 38723981
Background & Aims: The pivotal phase 3 True North (TN) study demonstrated the efficacy and safety of ozanimod in patients with moderately to severely active ulcerative colitis. This analysis assessed...
6.
Jang K, Ercelen D, Cen Feng J, Gurunathan S, Zhou C, Korman A, et al.
bioRxiv
. 2024 May;
PMID: 38712048
Background & Aims: Despite increasing therapeutic options in the treatment of ulcerative colitis (UC), achieving disease remission remains a major clinical challenge. Nonresponse to therapy is common and clinicians have...
7.
Malter L, Hong S, Lopatin S, Murphy M, Hudesman D, Kane S, et al.
Inflamm Bowel Dis
. 2024 Jan;
31(3):746-750.
PMID: 38217539
Background: Inflammatory bowel disease (IBD) management has become increasingly complex, and education varies across fellowship programs. IBD 101 was designed to introduce first-year gastroenterology (GI) fellows to IBD care and...
8.
Faye A, Lee K, Hudesman D, Dervieux T
Inflamm Bowel Dis
. 2024 Jan;
30(12):2509-2511.
PMID: 38170900
No abstract available.
9.
Herfarth H, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, et al.
Clin Transl Gastroenterol
. 2023 Dec;
15(3):e00669.
PMID: 38131617
Introduction: We previously reported the results of tofacitinib induction therapy in the prospective multisite US real-world Tofacitinib Response in Ulcerative Colitis registry. We now assessed patient-reported outcomes (PROs) and predictors...
10.
George L, Feldman H, Alizadeh M, Abutaleb A, Zullow S, Hine A, et al.
Crohns Colitis 360
. 2023 Oct;
5(4):otad059.
PMID: 37886705
Background: In ulcerative colitis (UC), endoscopic improvement, defined as a Mayo Endoscopic Score (MES) of 0 or 1, is a target of treatment. The aim of our study was to...